Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib dose-flexibility study in adults with moderate to severe atopic dermatitis
NL-OMON53671Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of upadacitinib in atopic dermatitis (AD) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Achievement of EASI 90 at Week 24. Started Sep 2023; status: completed.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON53671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53671.